Does pentoxifylline find a place in the armementarium of leprologists in type II reaction?

Indian Journal of Leprosy

Volumn 74, Issue 4, 2003, Pages 329-334

  Chatterjee, Manas ^a   Jaiswal, A K ^b  

^a MILITARY HOSPITAL   (India)

^b BASE HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE; PREDNISONE; STEROID;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LEPROSY; LONG TERM CARE; MALE; RECURRENT DISEASE; REMISSION; SIDE EFFECT; SUPERINFECTION; SYMPTOM; TREATMENT OUTCOME;

ADULT; BLOOD SEDIMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHEMA NODOSUM; HEMATOLOGIC AGENTS; HIV INFECTIONS; HUMANS; LEPROSY, LEPROMATOUS; MALE; MIDDLE AGED; PENTOXIFYLLINE; SKIN; TREATMENT OUTCOME;

EID: 0036826075     PISSN: 02549395     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA (1991). Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110: 192-8
2. Moraes MO, Sarno EN, Almeida AS, Saraiva BC, Nery JA, Martins RC, Sampaio EP (1999). Cytokine gene expression in leprosy: A possible role for IFN gamma and IL12 in reactions (RR and ENL). Scand J Immunol 50: 541-9
3. Moraes MO, Sarno EN, Teles RM, Almeida AS, Saraiva BC, Nery JA, Sampaio EP (2000). Anti-inflammatory drugs block cytokine mRNA accumulation in the skin and improve the clinical condition of reactional leprosy patients. J Invest Dermatol 115: 935-41
4. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993). Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 117: 1675-80
5. Nery JAC, Perisse ARS, Sales AM, Viera LM, Souza RV, Sampaio EP, Sarno EN (2000). The use of pentoxifylline in the treatment of Type II reactional episodes in leprosy. Indian J Lepr 72: 457-67
6. Sampaio EP, Moraes MO, Nery JA, Santos AR, Matos HC, Sarno EN (1998). Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-α) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL). Clin Exp Immunol 111: 300-8
7. Sarno EN, Nery JAC, Garcia CC, Sampaio EP (1995). Is pentoxifylline a viable alternative in the treatment of ENL? Int J Lepr 63: 570-1
8. Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP III, Larrick J, Kunkel SL (1988). Cellular and molecular regulation of tumor necrosis factor-α production by pentoxifylline. Biochem Biophys Res Commun 155: 1230-6
9. Ward A, Clissold SP (1987). Pentoxifylline: A review of tis pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34: 50-97
10. Welsh O, Gamez M, Mancias C, Ibarra-Leal S, Millikan LE (1999). A new therapeutic approach to Type II leprosy reaction. Int J Dermatol 38: 931-3